Analyst: Webjet share price target is $17

Are Webjet Limited (ASX:WEB) shares cheap?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

The News Corp press is reporting that professional investment analysts at RBC Capital Markets have slapped a $17 share price target on online travel business Webjet Limited (ASX: WEB).

Webjet shares have been volatile over 2019 as investors seem uncertain as to a fair value for this fast-growing business that has been on an acquisitive trail and run into an accounting dispute with its former auditor.

Prior to releasing its profit report for the six-month period ending December 31 2018 the stock closed for $11.37, yet two days later closed at $16.10 nearly 45% higher.

Since then it's dropped about 10% to $14.50 despite not releasing any news to the market, although investors may be getting nervous over the impact of the Brexit crisis in the UK given it recently acquired a huge amount of hotel inventory of UK travel giant Thomas Cook.

Still its business-to-business online bookings platforms are growing strongly and the UK is only a small part of its operations, with RBC analysts thinking it has plenty of room to run higher.

Others to have taken a knock recently in the travel space probably on the back of concerns about slowing global growth include Flight Centre Travel Group Ltd (ASX: FLT) and HelloWorld Ltd (ASX: HLO).

Motley Fool contributor Tom Richardson owns shares of Webjet Ltd. The Motley Fool Australia owns shares of and has recommended Flight Centre Travel Group Limited. The Motley Fool Australia owns shares of Helloworld Limited. The Motley Fool Australia has recommended Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy hump day session for the ASX.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »